Castle Biosciences, Inc.
CSTL
$21.98
$0.843.97%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 471.71% | 132.86% | 147.50% | 91.32% | 87.49% |
| Total Depreciation and Amortization | 78.91% | 11.56% | 10.13% | 15.49% | 13.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -31.65% | 45.10% | -16.78% | -10.90% | 22.74% |
| Change in Net Operating Assets | -74.13% | 127.69% | 1,149.67% | -61.38% | 125.21% |
| Cash from Operations | 31.09% | 365.64% | 733.86% | 73.13% | 409.78% |
| Capital Expenditure | -99.50% | -159.80% | -29.59% | -174.18% | -112.26% |
| Sale of Property, Plant, and Equipment | 133.33% | 100.00% | -33.33% | 0.00% | -98.39% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 443.38% | -15.99% | -42.58% | -152.99% | -34.74% |
| Cash from Investing | 175.21% | -52.34% | -39.19% | -218.80% | -71.17% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 27.78% | 33.33% | 68.57% | -2.86% | -5.88% |
| Issuance of Common Stock | 35.28% | 512.50% | -15.97% | 7.15% | -10.02% |
| Repurchase of Common Stock | -58.88% | -377.49% | -15.17% | -50.96% | -158.37% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -63.33% | 1,762.22% | -81.42% | 1,362.09% | -339.60% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 224.89% | 301.83% | 113.84% | -95.55% | 167.82% |